Everest Medicines

News

24 2018/06

Ian Woo Joins Everest Medicines as President and Chief Financial Officer; Named Managing Director of C-Bridge Capital
04 2018/06

Tetraphase Pharmaceuticals Announces Everest Medicines’ Submission of an Investigational New Drug Application for Eravacycline in Complicated Intra-Abdominal Infection to the China Food and Drug Admin
20 2018/02

Tetraphase Pharmaceuticals Enters Into Exclusive Development and Commercialization Agreement with Everest Medicines for Eravacycline in China.
05 2017/12

Arena eligible to receive up to $224M, including upfront and milestone payments, in addition to royalties.
27 2017/10

C-Bridge Capital specializes in the growing Chinese health care market and is using its expertise to identify emerging industry leaders and bring global innovation into China.

Copyright Everest Medicines 2020 云顶药业（苏州）有限公司苏ICP备20038571号 | Terms of Use | Privacy Policy | Disclaimers

沪公网安备 31010602006477号